INT-787
Phase 2Small molecule
INT-787 is one of 33 small molecule programs targeting Hepatitis. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
237 competitors in Hepatitis
#DrugCompanyPhaseTrials
1Actos
TakedaPhase 3
Cysteine Hydrochloride
NovartisPhase 3
Deltasone
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 3
Crestor
AstraZenecaPhase 3
Aquasol E
NNational Eye Institute (NEI)
Phase 3
Amoxil
GGlobal Antibiotics Research and Development Partnership
Phase 3
Prevnar
GSKPhase 3
Rimonabant
SanofiPhase 3
Hepatitis B Vaccine
SanofiPhase 3
Cenicriviroc
TTobira Therapeutics, Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for INT-787. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- IIntercept Pharmaceuticals